CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,155,662 | +2.2% | 355,930 | +26.5% | 0.01% | 0.0% |
| Q2 2023 | $15,801,165 | +32.5% | 281,460 | +6.8% | 0.01% | +25.0% |
| Q1 2023 | $11,925,025 | -34.6% | 263,653 | -41.2% | 0.00% | -42.9% |
| Q4 2022 | $18,232,947 | +4.1% | 448,535 | +67.4% | 0.01% | -12.5% |
| Q3 2022 | $17,512,000 | +23.2% | 267,962 | +14.6% | 0.01% | +33.3% |
| Q2 2022 | $14,216,000 | +11.3% | 233,919 | +15.0% | 0.01% | +50.0% |
| Q1 2022 | $12,769,000 | -11.3% | 203,432 | +7.1% | 0.00% | 0.0% |
| Q4 2021 | $14,390,000 | -7.9% | 189,890 | +36.0% | 0.00% | -20.0% |
| Q3 2021 | $15,631,000 | -16.6% | 139,653 | +20.6% | 0.01% | -16.7% |
| Q2 2021 | $18,742,000 | -35.3% | 115,774 | -51.3% | 0.01% | -40.0% |
| Q1 2021 | $28,985,000 | +40.0% | 237,879 | +75.9% | 0.01% | +42.9% |
| Q4 2020 | $20,710,000 | +165.7% | 135,261 | +45.1% | 0.01% | +133.3% |
| Q3 2020 | $7,795,000 | +25.7% | 93,193 | +10.4% | 0.00% | 0.0% |
| Q2 2020 | $6,202,000 | +113.3% | 84,394 | +23.1% | 0.00% | +200.0% |
| Q1 2020 | $2,907,000 | -15.4% | 68,546 | +21.6% | 0.00% | 0.0% |
| Q4 2019 | $3,435,000 | +84.4% | 56,393 | +24.1% | 0.00% | 0.0% |
| Q3 2019 | $1,863,000 | -30.6% | 45,457 | -20.2% | 0.00% | 0.0% |
| Q2 2019 | $2,683,000 | +33.2% | 56,964 | +1.0% | 0.00% | 0.0% |
| Q1 2019 | $2,015,000 | +38.3% | 56,394 | +10.6% | 0.00% | 0.0% |
| Q4 2018 | $1,457,000 | -59.7% | 50,994 | -37.5% | 0.00% | 0.0% |
| Q3 2018 | $3,617,000 | -25.4% | 81,554 | -1.2% | 0.00% | -50.0% |
| Q2 2018 | $4,849,000 | +78.6% | 82,525 | +38.9% | 0.00% | +100.0% |
| Q1 2018 | $2,715,000 | +4748.2% | 59,395 | +2406.1% | 0.00% | – |
| Q4 2017 | $56,000 | +460.0% | 2,370 | +315.8% | 0.00% | – |
| Q3 2017 | $10,000 | -60.0% | 570 | -62.7% | 0.00% | – |
| Q2 2017 | $25,000 | +108.3% | 1,528 | +168.1% | 0.00% | – |
| Q1 2017 | $12,000 | -85.4% | 570 | -85.9% | 0.00% | – |
| Q4 2016 | $82,000 | – | 4,042 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |